New therapy has potential to advance the treatment of pediatric cholestatic liver diseases

(European Association for the Study of the Liver) Results from a study of a novel ileal bile acid transport inhibitor, A4250, demonstrated that it reduced levels of blood bile acids, which are characteristic of many liver diseases and often associated with severe liver damage, in children with cholestatic liver diseases. The data, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, showed that oral treatment with A4250 improved itching in 74 percent of patients a...